Keywords: Merck KGaA, PDS Biotech, Versamune technology license, Cancer immunotherapies, Portugal R&D, Hospital debts

Merck KGaA acquires rights to PDS Biotech's technology; threatens action in Portugal

Article | 10 July 2012

Print This

Privately-held US biotech firm PDS Biotechnology says it has entered into an exclusive worldwide licensing agreement with Germany’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in